July 15, 2020
Eisai and the Alzheimer’s Clinical Trials Consortium (ACTC) have launched a PIII study in the US to test BAN2401 as a treatment for preclinical Alzheimer’s disease. The study, AHEAD 3-45, will be expanded to also include Japan, Canada, Australia, Singapore,...read more